Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In addition to being early to the defense tech and AI trends, Lux has realized significant exits from its investment in AI ...

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 4.1% and a 52.3% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Peter Krull, director of Earth Equity Advisors, discusses why he's bullish on renewable energy and shares his top clean ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...

On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...